Peter Van Ess

Dr. Peter Van Ess has over 30 years of experience in scientific research and management, including 20 years in the global pharmaceutical industry. Before joining DepYmed, Dr. Van Ess served as the Chief Scientific Officer at Proximagen LLC, where he oversaw research and development activities for a portfolio of programs in inflammation, oncology, and neurology; and played a large role in the successful spin-out of Proximagen LLC from Upsher-Smith Laboratories and the development and NDA approval of its lead program, Nayzilam®. Dr. Van Ess has held leadership and management positions in Clinical Pharmacology at Upsher-Smith Laboratories, deCODE genetics and Pfizer where he made substantial contributions to numerous INDs/CTAs and NDA/MAA approvals (Inspra® and Daxas®). In 2008, Dr. Van Ess co-founded the strategic drug development consultancy firm, Great Lakes Drug Development which was acquired by Certara in 2013. Dr. Van Ess received his Bachelor of Science Degrees in Bacteriology and Pharmacy and a Doctor of Pharmacy Degree (Pharm.D.) from the University of Wisconsin-Madison and a Ph.D. in Clinical Pharmacology and Experimental Therapeutics from the University of Kentucky-Lexington College of Pharmacy.